Seeing as therapeutic modulation of the RhoA/ROCK pathway also improves disease phenotypes in neurodegenerative models such as amyotrophic lateral sclerosis and Parkinson's disease [96,97], the perturbed GC-KLF15-BCAA activity may not be limited to SMA and DMD. This evidence concerns the gene SMN1 and Parkinson disease.